Bristol-Myers and AbbVie Speed Toward FDA Approval With a 'Breakthrough' Cancer Drug
Tuesday, September 1, 2015
Source: Fierce Biotech
The antibody, elotuzumab, is designed to train the immune system's attention on a protein called SLAMF7, expressed by tumor cells that might otherwise go unnoticed by the body's natural defenses. With the priority review tag, the agency promises to give Bristol-Myers and AbbVie a final decision within 6 months, shortening the standard 10-month time frame.